Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics Interaction Study of Azvudine and Itraconazole
NCT07001501Phase 1Completed
- Sponsor
- Genuine Biotech
- Start
- Feb 2022
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of azvudine in human immunodeficiency virus infection (HIV) and coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Genuine Biotech. Primary endpoints: Maximum Plasma Concentration at Steady State at Day 56, Time to Maximum Plasma Concentration at Steady State at Day 56 and 1 more. Started Feb 2022; status: completed.
02
Drugs
azvudine
03
Conditions
human immunodeficiency virus infection (HIV)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07001501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07001501.